

# Dilation of Schlemm's Canal during Glaucoma Surgery

<b>Submission date</b> 30/08/2010	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 07/10/2010	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 31/01/2012	<b>Condition category</b> Eye Diseases	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Ms Stephanie Baba

**Contact details**  
4055 Campbell Ave.  
Menlo Park  
United States of America  
94025

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**  
OMS-2005

## Study information

**Scientific Title**

Dilation of Schlemms Canal during Glaucoma Surgery: A multicenter, single arm, non-randomized interventional trial

### **Study objectives**

That the use of the iScience microcatheter in the treatment of open angle glaucoma is safe and effective.

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

The Freiburg Ethics Commission International (FECI) approved on the 8th of September 2005 (ref: 05/1462)

### **Study design**

Prospective multicentre single arm non-randomised interventional trial

### **Primary study design**

Interventional

### **Secondary study design**

Randomised controlled trial

### **Study setting(s)**

Hospital

### **Study type(s)**

Treatment

### **Participant information sheet**

Please contact the Clinical Affairs Department [clinical@iscienceinterventional.com] for more information or to request a patient information sheet

### **Health condition(s) or problem(s) studied**

Open-angle glaucoma

### **Interventions**

Canaloplasty, a procedure involving circumferential viscodilation and tensioning of the inner wall of Schlemms canal for the treatment of open-angle glaucoma This is a single-arm study. The total duration of follow-up is 3 years.

### **Intervention Type**

Other

### **Phase**

Not Applicable

### **Primary outcome measure**

1. Intraocular pressure in mm Hg, measured at baseline, 1 day, 1 week, and then at 1, 3, 6, 12, 18, 24, 30, and 36 months using tonometry.

2. Number of glaucomatous medications, obtained during patient visits and recorded via case report forms.

### **Secondary outcome measures**

1. Nature and frequency of surgical and post-surgical complications

2. Number of secondary interventions

Obtained during patient visits and recorded via case report forms.

### **Overall study start date**

08/09/2005

### **Completion date**

31/12/2009

## **Eligibility**

### **Key inclusion criteria**

1. At minimum 18 years of age

2. Scheduled for glaucoma surgery or combined cataract and glaucoma surgery

3. Diagnosis of primary open-angle glaucoma (POAG), pigmentary glaucoma, exfoliative glaucoma, or POAG mixed with another included mechanism

4. Baseline intraocular pressure of 16 mm Hg or higher and a historical IOP of 21 mm Hg or higher

5. Either sex

### **Participant type(s)**

Patient

### **Age group**

Adult

### **Lower age limit**

18 Years

### **Sex**

Both

### **Target number of participants**

157 eyes

### **Key exclusion criteria**

1. Neovascular disease

2. Uveitis

3. Peripheral anterior synechiae

4. Angle recession

5. Developmental or secondary glaucoma with the exception of pigmentary and exfoliative glaucoma

6. Previous ocular surgeries that would interfere with complete circumferential catheterization of Schlemms canal

7. Patients with more than two laser trabeculoplasty procedures

**Date of first enrolment**

08/09/2005

**Date of final enrolment**

31/12/2009

## **Locations**

**Countries of recruitment**

Germany

United States of America

**Study participating centre**

**4055 Campbell Ave.**

Menlo Park

United States of America

94025

## **Sponsor information**

**Organisation**

iScience Interventional Corp. (USA)

**Sponsor details**

4055 Campbell Ave

Menlo Park

United States of America

94025

**Sponsor type**

Industry

## **Funder(s)**

**Funder type**

Industry

**Funder Name**

iScience Interventional Corp (USA)

# Results and Publications

## Publication and dissemination plan

Not provided at time of registration

## Intention to publish date

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/10/2011		Yes	No